IP Library Granted Patent US 12,365,927
Granted Patent B2
US 12,365,927 · App. 18/049,758 · Granted Jul 22, 2025

Engineered ketoreductase polypeptides

Inventors: Christopher Savile (Santa Clara, CA); John M. Gruber (El Dorado Hills, CA); Emily Mundorff (Garden City, NY); Gjalt W. Huisman (Redwood City, CA); Steven J. Collier (Concord, MA)
Assignee: Codexis, Inc.
C12P17/00C12N9/0006C12P13/001C12Y101/01164C12Y101/01184
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,365,927
App. No.
18/049,758
Granted
Jul 22, 2025
Kind
B2
Abstract

The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds. The engineered ketoreductase polypeptides are optimized for catalyzing the conversion of N-methyl-3-keto-3-(2-thienyl)-1-propanamine to (S)—N-methyl-3-hydroxy-3-(2-thienyl)-1-propanamine.

Claims (7)

1. A ketoreductase polypeptide capable of converting substrate N-methyl-3-keto-3-(2-thienyl)-1-propanamine to product (S)—N-methyl-3-hydroxy-3-(2-thienyl)-1-propanamine at a rate that is improved over a reference polypeptide having the amino acid sequence of SEQ ID NO:6, wherein the polypeptide has an amino acid sequence that is at least 90% identical to a reference sequence based on SEQ ID NO:2, comprising a residue substitution relative to SEQ ID NO: 2 at one or more positions selected from 40, 46, 60, 64, 108, 145, 152, 153, 157, 190, 196, 198, 199, 226, 245, and 249.

2. The ketoreductase polypeptide of claim 1 , wherein the residue substitution at position 190 is cysteine, proline, or a constrained amino acid; the residue substitution at position 46 is arginine; the residue substitution at position 60 is isoleucine; the residue substitution at position 64 is valine; the residue substitution at position 108 is histidine; the residue substitution at position 152 is asparagine; the residue substitution at position 153 is valine; the residue substitution at position 157 is serine; the residue substitution at position 198 is asparagine; and/or the residue substitution at position 245 is isoleucine.

3. The ketoreductase polypeptide of claim 1 , wherein the polypeptide is capable of converting the substrate to the product with a percent stereomeric excess of at least 95%.

4. The ketoreductase polypeptide of claim 1 , wherein the polypeptide is capable of converting the substrate to the product with a percent stereomeric excess of at least 99%.

5. The ketoreductase polypeptide of claim 1 , wherein the polypeptide is capable of converting the substrate to the product at a rate that is at least 10-15 times greater than the rate of conversion of the substrate to the product by the reference polypeptide of SEQ ID NO:6.

6. The ketoreductase polypeptide of claim 1 , wherein the polypeptide is capable of converting the substrate to the product at a rate that is at least 15 times greater than the rate of conversion of the substrate to the product by the reference polypeptide of SEQ ID NO:6.

7. The ketoreductase polypeptide of claim 1 , wherein the polypeptide is capable of converting at least 95% of the substrate to the product in less than about 24 hours when carried out with greater than 100 g/L of substrate and less than 5 g/L of the polypeptide.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (9)
Continuation 16932084 · Jul 17, 2020
Continuation 15982291 · May 17, 2018
Division 15489946 · Apr 18, 2017
Division 14954564 · Nov 30, 2015
Continuation 14503578 · Oct 1, 2014
Continuation 13610166 · Sep 11, 2012
Division 12549293 · Aug 27, 2009
Provisional Application 61092331 · Aug 27, 2008
Related Publication 20230104779A1 · Apr 6, 2023
References Cited (73)
US 4956388A · Robertson et al. · 1990 [cited by applicant]
US 5023269A · Robertson et al. · 1991 [cited by applicant]
US 5200335A · Hummel et al. · 1993 [cited by applicant]
US 5362886A · Berglund · 1994 [cited by applicant]
US 5491243A · Berglund · 1996 [cited by applicant]
US 5559030A · Matsuyama et al. · 1996 [cited by applicant]
US 6037158A · Hummel et al. · 2000 [cited by applicant]
US 6225099B1 · Hummel et al. · 2001 [cited by applicant]
US 6399339B1 · Wolberg et al. · 2002 [cited by applicant]
US 6531308B2 · Hershberger et al. · 2003 [cited by applicant]
US 6541668B1 · Kjell et al. · 2003 [cited by applicant]
US 6645746B1 · Kizaki et al. · 2003 [cited by applicant]
US 6800477B2 · Patel et al. · 2004 [cited by applicant]
US 6846957B2 · Zelenin · 2005 [cited by applicant]
US 7045341B2 · Kamal et al. · 2006 [cited by applicant]
US 7259264B2 · Sturmer · 2007 [cited by applicant]
US 7301031B2 · Rozzell, Jr. et al. · 2007 [cited by applicant]
US 7393667B2 · Patel et al. · 2008 [cited by applicant]
US 7435563B2 · Sturmer · 2008 [cited by applicant]
US 7488833B2 · Kralik et al. · 2009 [cited by applicant]
US 7498448B2 · Sturmer et al. · 2009 [cited by applicant]
US 7538232B2 · Butchko et al. · 2009 [cited by applicant]
US 7553970B2 · Berendes et al. · 2009 [cited by applicant]
US 8288141B2 · Savile et al. · 2012 [cited by applicant]
US 8877475B2 · Savile et al. · 2014 [cited by applicant]
US 9228213B2 · Savile et al. · 2016 [cited by applicant]
US 9657320B2 · Savile et al. · 2017 [cited by applicant]
US 10006069B2 · Savile et al. · 2018 [cited by applicant]
US 10752926B2 · Savile et al. · 2020 [cited by applicant]
US 11512332B2 · Savile · 2022 [cited by examiner]
US 20030181319A1 · Tucker et al. · 2003 [cited by applicant]
US 20040023250A1 · Nanduri et al. · 2004 [cited by applicant]
US 20050197503A1 · Schiffers et al. · 2005 [cited by applicant]
US 20060167278A1 · Inoue et al. · 2006 [cited by applicant]
US 20060211099A1 · Althofer et al. · 2006 [cited by applicant]
US 20060264641A1 · Berendes et al. · 2006 [cited by applicant]
US 20070238883A1 · Ini et al. · 2007 [cited by applicant]
US 20080005078A1 · Dampier et al. · 2008 [cited by applicant]
US 20080050787A1 · Nagai et al. · 2008 [cited by applicant]
US 20080206824A1 · Sturmer et al. · 2008 [cited by applicant]
US 20080220484A1 · Breuer et al. · 2008 [cited by applicant]
US 20080318288A1 · Sturmer et al. · 2008 [cited by applicant]
EP 0273658B1 · 1990 [cited by applicant]
EP 0457559A2 · 1991 [cited by applicant]
EP 0650965B1 · 2001 [cited by applicant]
EP 1506965A1 · 2005 [cited by applicant]
EP 1566383A1 · 2005 [cited by applicant]
EP 1171417B1 · 2005 [cited by applicant]
EP 1587801B1 · 2007 [cited by applicant]
EP 1539673B1 · 2007 [cited by applicant]
IN 1573DEL2004 · 2006 [cited by applicant]
WO 2003062219A1 · 2003 [cited by applicant]
WO 2004005239A1 · 2004 [cited by applicant]
WO 2004005307A1 · 2004 [cited by applicant]
WO 2004011452A1 · 2004 [cited by applicant]
WO 2004055194A1 · 2004 [cited by applicant]
WO 2005021527A2 · 2005 [cited by applicant]
WO 2005080370A1 · 2005 [cited by applicant]
WO 2004031168A2 · 2007 [cited by applicant]
WO 2007095200A2 · 2007 [cited by applicant]
WO 2007143065A2 · 2007 [cited by applicant]
Cooley, J.H., et al., “Amine Dealkylations with Acyl Chlorides”, Synthesis, 1:1-7, 1989. [cited by applicant]
Deeter, J., et al., “Asymmetric Synthesis and Absolute Stereochemistry of LY248686”, Tetrahedron Letters, 31 (49):7101-7104, 1990. [cited by applicant]
He, S. Z., et al., “Synthesis of Antidepressant Duloxetine Via Asymmetric Transfer Hydrogenation”, Chinese Chemical Letters, 19: 23-25, 2008. [cited by applicant]
Kamal, A., et al., Chemoenzymatic Synthesis of Duloxetine and its Enantiomer: Lipase-Catalyzed Resolution of 3-hydroxy-3-(2-thienyl) propanenitrile, Tetrahedron Letters, 44:4783-4787, 2003. [cited by applicant]
Liu, D., et al., “Practical Synthesis of Enantiopure Gamma-Amino Alcohols by Rhodium-Catalyzed Asymmetric Hydrogenation of Beta-Secondary-Amino Ketones”, Angewandte Chemie, 44:1687-1689, 2005. [cited by applicant]
Liu, H., et al., “Chemo-Enzymatic Synthesis of the Antidepressant Duloxetine and its Enantiomer”, Chirality, 12:26-29, 2000. [cited by applicant]
Niefind, K., et al., “The Crystal Structure of R-Specific Alcohol Dehydrogenase from Lactobacillus brevis Suggests the Structural Basis of its Metal Dependency”, J. Mol. Biol., 327:317-328, 2003. [cited by applicant]
Sakai, K., et al., “Resolution of 3-(methylamino)-1-(2-thienyl)propan-1-ol, a New Key Intermediate for Duloxetine, with (S)-mandelic Acid”, Tetrahedron: Asymmetry, 14:1631-1636, 2003. [cited by applicant]
Schneider, F., et al., “NADPH dependent R-specific alcohol dehydrogenase [Lactobacillus kefiri]”, NCBI Database, AAP94029 (submitted 2003). [cited by applicant]
Niefind, K., et al., “Chain A, Crystal Structure of R-Alcohol Dehydrogenase (Radh) (Apoenyzme) From Lactobacillus brevis”, NCBI database, 1NXQ_A (submitted 2003). [cited by applicant]
Goldberg, K., et al., “Biocatalytic ketone reduction-a powerful tool for the production of chiral alcohols-part II: whole-cell reductions,” Applied Microbiology and Biotechnology, 76(2):249-255, Aug. 2007. [cited by applicant]
Fujima, Y., et al., “Synthesis of (S)-3-(N-Methylamino)-1-(2-thienyl)propan-1-ol: Revisiting Eli Lilly's Resolution-Racemization-Recycle Synthesis of Duloxetine for Its Robust Processes,” Organic Process Research & Deve… [cited by applicant]